Condition: Leptomeningeal Disease · Sponsor: University Hospital Tuebingen
To determine the safety of intrathecal (IT) PD1 antibody for Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease of solid tumors.
This description comes directly from the study's public registry record.
Ghazaleh Tabatabai, Prof.Dr. · +49 (0) 7071 - 2985018 · ghazaleh.tabatabai@uni-tuebingen.de
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Bonn | Bonn, Germany | Recruiting |
| University Hospital Freiburg, Neurosurgery | Freiburg im Breisgau, Germany | Recruiting |
| University Hospital Heidelberg, Neurooncology | Heidelberg, Germany | Not Yet Recruiting |
| SLK-Kliniken Heilbronn GmbH Klinik | Heilbronn, Germany | Recruiting |
| University Hospital Mannheim, Neurology Clinic | Mannheim, Germany | Recruiting |
| Klinikum rechts der Isar/Technische Universität München | München, Germany | Recruiting |
| Katharinenhospital Stuttgart | Stuttgart, Germany | Recruiting |
| University Hospital Tübingen, Neurooncology | Tübingen, Germany | Recruiting |
| University Hospital Ulm, ECTU - Early Clinical Trail Unit | Ulm, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05112549